Transmedics

TMDX

Market cap $5B

As contradictory as it may sound, my most financially painful transaction has been one of my best investing lessons. These lessons apply to many stocks that I hold, but one in particular stands out today.

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 50-day moving average, which suggests a short-term bullish trend.

From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ANDOVER, Mass. , Nov. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference at the Lotte New York Palace.

Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future.

The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.

During the third quarter of 2025, the U.S. Small Cap Growth Composite Portfolio returned 21.4% gross and 21.1% net of fees. Bloom Energy is a provider of solid oxide fuel cells that play a critical role in delivering clean, reliable, 'always on' power at scale. Oddity Tech is a digital beauty and wellness platform that uses AI and data science to develop and recommend personalized products based on unique skin type and color signatures.

ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 27,582 shares of its common stock and an aggregate of 18,299 restricted stock units to 15 employees, each as a material inducement for each employee's entry into employment with TransMedics.

TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the company's valuation in the long term.